explore -WSS

explore

author：Wikipedia 2025-09-28 20:31:54 - browse：828

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： NIH chief: government has fallen behind pharma on clinical trials

WSS

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Bernie Sanders bashes nonprofit hospitals over their tax breaks

What the Wegovy shortage looks like for doctors — and for patients

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Peter Marks talks Operation Warp Speed for Rare Diseases

How should state employee insurance handle Wegovy?

focus

explore

hotspot

Drug repurposing or repositioning? The language matters

Cancer cells are shown to suck energy source from immune cells

23andMe had bad news about my health. I wish a person had delivered it

What is STAT's opinion section for?

Affirmative action in medical school literally saved lives

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Life sciences deals on track to hit lowest point since 2017

Walensky prepares to leave CDC — and Congress — behind

Eight reasons why you should get an updated Covid vaccine

explore

How state and local governments are sidelining science

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Researchers CRISPR chickens in bid to protect them from bird flu

FDA reorg will put new emphasis on investigations, sources say

Researchers CRISPR chickens in bid to protect them from bird flu

Cancer diagnosis changes perspective doctor, former hospital CEO

entertainment

hotspot

hotspot

Wikipedia